17.09.2011 • News

Alkermes Announce Completion Of Merger Between Alkermes And Elan Drug Tech

Alkermes and Elan Corporation announced the completion of the merger between Alkermes and Elan Drug Technologies , the drug formulation and manufacturing business unit of Elan. The businesses were combined under a newly-formed company, Alkermes, which is incorporated in Ireland and headquartered in Dublin.

Under the terms of the business combination agreement, Elan Corporation receives $500 million in cash and 31.9 million ordinary shares of Alkermes, representing approximately 25% of Alkermes. Based on the closing share price of Alkermes on September 15, 2011 of $16.52, this represents a total transaction value of approximately $1.0 billion.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Top-Feature

most read